Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,728,536 papers from all fields of science
Search
Sign In
Create Free Account
Cytarabine
Known as:
Cytosine-.beta.-arabinoside
, Cytosine-beta-arabinoside
, Arabinoside, Cytosine
Expand
An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
45 relations
Narrower (24)
2'-fluoro-5-methylarabino-furanosylcytosine
5'-palmitoyl cytarabine
5-methyl ara-C
Ara-C
Expand
COPAD protocol
F-MACHOP Regimen
Larson Regimen
VAPAC protocol
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1999
Highly Cited
1999
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
C. Dumontet
,
K. Fabianowska-Majewska
,
+12 authors
J. Mackey
British Journal of Haematology
1999
Corpus ID: 26515296
Resistant variants of the human leukaemic line K562 were developed using selection with the deoxynucleoside analogues cytosine…
Expand
Highly Cited
1988
Highly Cited
1988
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
V. Gandhi
,
W. Plunkett
Cancer Research
1988
Corpus ID: 20763024
Previous studies have indicated that deoxycytidine kinase (dCK) is requisite and rate limiting in the phosphorylation of 1-beta-D…
Expand
Highly Cited
1985
Highly Cited
1985
Progressive multifocal leukoencephalopathy: Clinical and radiographic features
L. Krupp
,
R. Lipton
,
M. Swerdlow
,
N. Leeds
,
J. Llena
Annals of Neurology
1985
Corpus ID: 24867175
Between April 1982 and March 1984 7 pathologically confirmed cases of progressive multifocal leukoencephalopathy (PML) were…
Expand
Highly Cited
1985
Highly Cited
1985
High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
R. Herzig
,
H. Lazarus
,
S. Wolff
,
G. Phillips
,
G. Herzig
Journal of Clinical Oncology
1985
Corpus ID: 22585261
Seventy-eight patients with acute nonlymphoblastic leukemia in relapse were treated with high-dose cytosine arabinoside (3 g/m2…
Expand
Highly Cited
1985
Highly Cited
1985
Somatomedin-C synergizes with follicle-stimulating hormone in the acquisition of progestin biosynthetic capacity by cultured rat granulosa cells.
E. Adashi
,
C. Resnick
,
M. Svoboda
,
J. V. Van Wyk
Endocrinology
1985
Corpus ID: 28809843
We have recently shown that nanomolar concentrations of somatomedin-C (Sm-C), are capable of enhancing the FSH-mediated (but not…
Expand
Review
1976
Review
1976
Bisulfite modification of nucleic acids and their constituents.
H. Hayatsu
Progress in Nucleic Acid Research and Molecular…
1976
Corpus ID: 45882162
Highly Cited
1974
Highly Cited
1974
The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
B. F. Cain
,
G. Atwell
European Journal of Cancer
1974
Corpus ID: 20582401
Highly Cited
1971
Highly Cited
1971
Effects of hydroxyurea and 1-beta-D-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells.
Lambert Skoog
,
B. Nordenskjöld
European Journal of Biochemistry
1971
Corpus ID: 44621432
Mouse embryo cells incubated in medium with 0.5% serum contain only few cells which synthesize DNA. When the serum concentration…
Expand
Highly Cited
1968
Highly Cited
1968
The incorporation of 3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y).
Ming Y. Chu
,
Glenn A. Fischer
Biochemical Pharmacology
1968
Corpus ID: 32348398
Review
1966
Review
1966
Introduction to the biochemistry of D-arabinosyl nucleosides.
Seymour S. Cohen
Progress in Nucleic Acid Research and Molecular…
1966
Corpus ID: 35563820
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE